Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance.

Gold MS, McIntyre P.

Sex Health. 2010 Sep;7(3):320-4. doi: 10.1071/SH09153.

PMID:
20719221
2.

Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.

Brotherton JM, Kaldor JM, Garland SM.

Sex Health. 2010 Sep;7(3):310-9. doi: 10.1071/SH09137.

PMID:
20719220
3.

Low rates of free human papillomavirus vaccine uptake among young women.

Moore GR, Crosby RA, Young A, Charnigo R.

Sex Health. 2010 Sep;7(3):287-90. doi: 10.1071/SH09136.

PMID:
20719216
4.

Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.

Budd AC, Sturrock CJ.

Sex Health. 2010 Sep;7(3):328-34. doi: 10.1071/SH09133.

PMID:
20719223
5.

Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine.

Brotherton JM, Fairley CK, Garland SM, Gertig D, Saville M.

Sex Health. 2010 Sep;7(3):397-8. No abstract available.

PMID:
21058499
6.

National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program.

Brotherton JM, Leask J, Jackson C, McCaffery K, Trevena LJ.

Sex Health. 2010 Sep;7(3):291-8. doi: 10.1071/SH09135.

PMID:
20719217
7.

For debate: that Australia should continue using the quadrivalent vaccine.

Wain G.

Sex Health. 2010 Sep;7(3):235-7. No abstract available.

PMID:
21058496
8.

Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women.

Pitts MK, Heywood W, Ryall R, Smith AM, Shelley JM, Richters J, Simpson JM.

Sex Health. 2010 Sep;7(3):299-303. doi: 10.1071/SH09150.

PMID:
20719218
9.

Quadrivalent HPV vaccination reactions--more hype than harm.

Douglas RJ.

Aust Fam Physician. 2009 Mar;38(3):139-42.

10.

Human papillomavirus vaccines: an update for gynecologists.

Ault KA.

Clin Obstet Gynecol. 2008 Sep;51(3):527-32. doi: 10.1097/GRF.0b013e31818092df. Review.

PMID:
18677145
11.
12.

Commentary on opinion pieces re Australian human papillomavirus vaccine policy.

McIntyre P.

Sex Health. 2010 Sep;7(3):242-3. No abstract available.

PMID:
21058498
13.

Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience.

Heffernan ME, Garland SM, Kane MA.

Sex Health. 2010 Sep;7(3):383-90. doi: 10.1071/SH09134.

PMID:
20719231
14.

Cancers attributable to human papillomavirus infection.

Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.

Sex Health. 2010 Sep;7(3):244-52. doi: 10.1071/SH10020.

PMID:
20719211
15.

A brief history of economic evaluation for human papillomavirus vaccination policy.

Beutels P, Jit M.

Sex Health. 2010 Sep;7(3):352-8. doi: 10.1071/SH10018.

PMID:
20719227
16.

'It's a logistical nightmare!' Recommendations for optimising human papillomavirus school-based vaccination experience.

Robbins SC, Bernard D, McCaffery K, Skinner SR.

Sex Health. 2010 Sep;7(3):271-8. doi: 10.1071/SH09140.

PMID:
20719214
17.

What can surveillance of genital warts tell us?

Fairley CK, Donovan B.

Sex Health. 2010 Sep;7(3):325-7. doi: 10.1071/SH09145. Review.

PMID:
20719222
18.

Models of cervical screening in the era of human papillomavirus vaccination.

Canfell K.

Sex Health. 2010 Sep;7(3):359-67. doi: 10.1071/SH10016.

PMID:
20719228
19.

Cervical cancer vaccine development.

Frazer IH.

Sex Health. 2010 Sep;7(3):230-4. doi: 10.1071/SH09132. Review.

PMID:
20719210
20.

Supplemental Content

Support Center